Ensysce Biosciences (ENSC) Other financing activities (2021 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Other financing activities of $1.5 million for Q3 2025, up 469.39% year-over-year from $262885.1 in Q3 2024, and up 3392.43% quarter-over-quarter from $42860.0 in Q2 2025.
Ensysce Biosciences (ENSC) Other financing activities (2021 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Other financing activities for 4 consecutive years, with $1.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Other financing activities rose 469.39% year-over-year to $1.5 million; the TTM figure through Sep 2025 stood at $2.7 million (up 58.73% YoY), while the FY2024 annual figure was $2.4 million, down 73.12% from the prior year.
- Other financing activities grew to $1.5 million in Q3 2025 per ENSC's latest filing, from $42860.0 in the prior quarter.
- Across five years, Other financing activities topped out at $6.4 million in Q2 2023 and bottomed at -$405218.0 in Q3 2024.
- Historically, Other financing activities has averaged $1.5 million across 4 years, with a median of $763079.0 in 2024.
- On a YoY basis, Other financing activities climbed as much as 469.39% in 2025 and fell as far as 83.23% in 2025.
- Ensysce Biosciences' Other financing activities stood at $262862.0 in 2021, then jumped by 2319.88% to $6.4 million in 2023, then tumbled by 88.0% to $763079.0 in 2024, then surged by 96.16% to $1.5 million in 2025.
- Business Quant data shows ENSC's Other financing activities at $1.5 million in Q3 2025, $42860.0 in Q2 2025, and $347995.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 42,860.00 |
| Jun 30, 2025 | 42,860.00 |
| Mar 31, 2025 | 347,995.00 |
| Mar 31, 2025 | 347,995.00 |
| Dec 31, 2024 | 763,079.00 |
| Dec 31, 2024 | 763,079.00 |
| Sep 30, 2024 | -405,218.00 |
| Sep 30, 2024 | -405,218.00 |
| Mar 31, 2024 | 2.08 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Jun 30, 2023 | 6.36 Mn |
| Jun 30, 2023 | 6.36 Mn |
| Mar 31, 2023 | 2.69 Mn |
| Mar 31, 2023 | 2.69 Mn |
| Mar 31, 2021 | 262,862.00 |
| Mar 31, 2021 | 262,862.00 |